Evidence map›Paper›PMID 31905401›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2020

Effects of Influenza Vaccination in the United States During the 2018-2019 Influenza Season.

Jessie R Chung, Melissa A Rolfes, Brendan Flannery, Pragati Prasad, Alissa O'Halloran, Shikha Garg, Alicia M Fry, James A Singleton, Manish Patel, Carrie Reed and 1 more

Abstract read
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Influenza vaccine effectiveness against outpatient acute respiratory illness with laboratory-confirmed influenza, United States, 2024-25 season.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Estimated impact of 2022-2023 influenza vaccines on annual hospital burden in the United States.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jessie R ChungInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Melissa A RolfesInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Brendan FlanneryInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Pragati PrasadInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Alissa O'HalloranInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Shikha GargInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Alicia M FryInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
James A SingletonImmunization Services Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Manish PatelInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Carrie ReedInfluenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
US Influenza Vaccine Effectiveness Network, the Influenza Hospitalization Surveillance Network, and the Assessment Branch, Immunization Services Division, Centers for Disease Control and Prevention

Funding

University of Pittsburgh Clinical and Translational Science InstituteUL1TR001857 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2016 to 2025
$129.3M
US Influenza Vaccine Effectiveness NetworkU01IP001034 · IP · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MONTO, ARNOLD S · 2016 to 2020
$10.0M
Annual Estimates of Influenza Vaccine Effectiveness and Evaluation of Immune Response in a Wisconsin PopulationU01IP001038 · IP · MARSHFIELD CLINIC RESEARCH FOUNDATION · PI BELONGIA, EDWARD · 2016 to 2020
$8.0M
Prospective annual estimates of influenza vaccine effectiveness and burden of diseaseU01IP001037 · IP · KAISER FOUNDATION RESEARCH INSTITUTE · PI JACKSON, MICHAEL L · 2016 to 2020
$7.8M
Outpatient VE for seasonal flu, pandemic flu and RSV in a large, diverse networkU01IP001035 · IP · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ZIMMERMAN, RICHARD K · 2016 to 2020
$7.8M
Mandatory_Estimates of Vaccine Effectiveness Against Medically-Attended, PCR-Confirmed Influenza in West South Central U.S.U01IP001039 · IP · SCOTT AND WHITE MEMORIAL HOSPITAL · PI GAGLANI, MANJUSHA · 2016 to 2020
$6.5M
NCATS NIH HHS UL1 TR001857NCIRD CDC HHS U01 IP000974NCIRD CDC HHS U01 IP001034NCIRD CDC HHS U01 IP001035NCIRD CDC HHS U01 IP001037NCIRD CDC HHS U01 IP001038NCIRD CDC HHS U01 IP001039OSTLTS CDC HHS U38 OT000143
6 · The paper itself

Abstract

backgroundMultivalent influenza vaccine products provide protection against influenza A(H1N1)pdm09, A(H3N2), and B lineage viruses. The 2018-2019 influenza season in the United States included prolonged circulation of A(H1N1)pdm09 viruses well-matched to the vaccine strain and A(H3N2) viruses, the majority of which were mismatched to the vaccine. We estimated the number of vaccine-prevented influenza-associated illnesses, medical visits, hospitalizations, and deaths for the season.

methodsWe used a mathematical model and Monte Carlo algorithm to estimate numbers and 95% uncertainty intervals (UIs) of influenza-associated outcomes prevented by vaccination in the United States. The model incorporated age-specific estimates of national 2018-2019 influenza vaccine coverage, influenza virus-specific vaccine effectiveness from the US Influenza Vaccine Effectiveness Network, and disease burden estimated from population-based rates of influenza-associated hospitalizations through the Influenza Hospitalization Surveillance Network.

resultsInfluenza vaccination prevented an estimated 4.4 million (95%UI, 3.4 million-7.1 million) illnesses, 2.3 million (95%UI, 1.8 million-3.8 million) medical visits, 58 000 (95%UI, 30 000-156 000) hospitalizations, and 3500 (95%UI, 1000-13 000) deaths due to influenza viruses during the US 2018-2019 influenza season. Vaccination prevented 14% of projected hospitalizations associated with A(H1N1)pdm09 overall and 43% among children aged 6 months-4 years.

conclusionsInfluenza vaccination averted substantial influenza-associated disease including hospitalizations and deaths in the United States, primarily due to effectiveness against A(H1N1)pdm09. Our findings underscore the value of influenza vaccination, highlighting that vaccines measurably decrease illness and associated healthcare utilization even in a season in which a vaccine component does not match to a circulating virus.

Indexed as

Influenza A Virus, H1N1 SubtypeInfluenza, HumanInfluenza VaccinesChildHumansInfluenza A Virus, H3N2 SubtypeInfluenza B virusSeasonsUnited StatesVaccinationInfluenza Vaccinesburdeninfluenzaprevented illnessesvaccination

Identifiers

PMID31905401
PMCPMC7643742

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.